ID   U87.CD4.CXCR4
AC   CVCL_X632
SY   U87.CD4-CXCR4; U87 CD4+CXCR4+
DR   cancercelllines; CVCL_X632
DR   HIVReagentProgram; ARP-4036
DR   Wikidata; Q54973769
RX   PubMed=9311827;
RX   PubMed=15169555;
WW   http://www.nibsc.org/Default.aspx?pageid=597&id=0073&theme=default
CC   Problematic cell line: Misidentified. Grand-parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: HGNC; 1678; CD4.
CC   Transfected with: HGNC; 2561; CXCR4.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR).
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_X626 ! U87.CD4
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 05-10-23; Version: 13
//
RX   PubMed=9311827; DOI=10.1128/JVI.71.10.7478-7487.1997;
RA   Bjorndal A., Deng H.-K., Jansson M., Fiore J.R., Colognesi C.,
RA   Karlsson A., Albert J., Scarlatti G., Littman D.R., Fenyo E.-M.;
RT   "Coreceptor usage of primary human immunodeficiency virus type 1
RT   isolates varies according to biological phenotype.";
RL   J. Virol. 71:7478-7487(1997).
//
RX   PubMed=15169555; DOI=10.1186/1742-4690-1-2;
RA   Princen K., Hatse S., Vermeire K., De Clercq E., Schols D.;
RT   "Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line
RT   which is highly sensitive to HIV and suitable for high-throughput
RT   evaluation of CCR5 and CXCR4 antagonists.";
RL   Retrovirology 1:2.1-2.13(2004).
//